1. Verma S, Devaraj S, Jialal I (2006) Is C-reactive protein an innocent bystander
or proatherogenic culprit? C-reactive protein promotes atherothrombosis.
Circulation 113: 2135–2150.
2. Pepys MB, Hawkins PN, Kahan MC, Tennent GA, Gallimore JR, et al. (2005)
Proinflammatory effects of bacterial recombinant human C-reactive protein are
caused by contamination with bacterial products, not by C-reactive protein itself.
Circ Res 97: e97–103.
3. Koenig W, Khuseyinova N (2007) Biomarkers of atherosclerotic plaque
instability and rupture. Arterioscler Thromb Vasc Biol 27: 15–26.
4. Danesh J, Collins R, Appleby P, Peto R (1998) Association of fibrinogen, Creactive
protein, albumin, or leukocyte count with coronary heart disease: metaanalyses
of prospective studies. JAMA 279: 1477–1482.
5. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, et al. (2004) Creactive
protein and other circulating markers of inflammation in the prediction
of coronary heart disease. N Engl J Med 350: 1387–1397.
6. Lawlor DA, Davey Smith G, Rumley A, Lowe GD, Ebrahim S (2005)
Associations of fibrinogen and C-reactive protein with prevalent and incident
coronary heart disease are attenuated by adjustment for confounding factors.
British Women’s Heart and Health Study. Thromb Haemost 93: 955–963.
7. Kivima¨ki M, Lawlor DA, Juonala M, Davey Smith G, Elovainio M, et al. (2005)
Lifecourse socioeconomic position, C-reactive protein, and carotid intima-media
thickness in young adults: the Cardiovascular Risk in Young Finns Study.
Arterioscler Thromb Vasc Biol 25: 2197–2202.
8. Wang TJ, Nam BH, Wilson PW, Wolf PA, Levy D, et al. (2002) Association of
C-reactive protein with carotid atherosclerosis in men and women: the
Framingham Heart Study. Arterioscler Thromb Vasc Biol 22: 1662–1667.
9. Lorenz MW, Karbstein P, Markus HS, Sitzer M (2007) High-Sensitivity Creactive
Protein Is Not Associated With Carotid Intima-Media Progression. The
Carotid Atherosclerosis Progression Study. Stroke 38: 1774–1779.
10. Bots ML (2006) Carotid intima-media thickness as a surrogate marker for
cardiovascular disease in intervention studies. Cur Med Res Opinion 22:
2181–2190.
11. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M (2007) Prediction of
clinical cardiovascular events with carotid intima-media thickness: a systematic
review and meta-analysis. Circulation 115: 459–467.
12. Davey Smith G, Lawlor DA, Harbord R, Timpson N, Rumley A, et al. (2005)
Association of C-Reactive Protein With Blood Pressure and Hypertension. Life
Course Confounding and Mendelian Randomization Tests of Causality.
Arterioscler Thromb Vasc Biol 25: 1051–1056.
13. Lowe GDO, Pepys MB (2006) C-reactive protein and cardiovascular disease:
weighing the evidence. Current Atherosclerosis Reports 8: 421–428.
14. Dhingra R, Gona P, Nam BH, D’Agostino RB Sr, Wilson PW, et al. (2007) Creactive
protein, inflammatory conditions, and cardiovascular disease risk.
Am J Med 120: 1054–1062.
15. Davey Smith G, Ebrahim S (2003) ‘Mendelian randomization’: can genetic
epidemiology contribute to understanding environmental determinants of
disease? Int J Epidemiol 32: 1–22.
16. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G (2007)
Mendelian randomization: Using genes as instruments for making causal
inferences in epidemiology. Stat Med 27: 1133–1163.
17. Hingorani A, Humphries S (2005) Nature’s randomised trials. Lancet 366:
1906–1908.
18. Davey Smith G, Lawlor DA, Harbord R, Timpson N, Day I, et al. (2007)
Clustered environments and randomized genes: A fundamental distinction
between conventional and genetic epidemiology. PLoS Med 4: e352.
19. Casas JP, Shah T, Cooper J, Hawe E, McMahon AD, et al. (2003) Insight into
the nature of the CRP-coronary event association using Mendelian randomization.
Int J Epidemiol 35: 922–931.
20. Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, et al. (2005) Creactive
protein and its role in metabolic syndrome: Mendelian randomisation
study. Lancet 366: 1954–1959.
21. Kivima¨ki M, Lawlor DA, Davey Smith G, Eklund C, Hurme M, et al. (2007)
Variants in the CRP gene as a measure of lifelong differences in average Creactive
protein levels: the Cardiovascular Risk in Young Finns Study, 1980–
2001. Am J Epidemiol 166: 760–764.
22. Kivima¨ki M, Lawlor DA, Eklund C, Davey Smith G, Hurme M, et al. (2007)
Mendelian randomization suggests no causal association between C-reactive
protein and carotid intima-media thickness in the young Finns study.
Arterioscler Thromb Vasc Biol 27: 978–979.
23. Bots ML, Hofman A, Grobbee DE (2007) Increased common carotid intimamedia
thickness. Adaptive response or a reflection of atherosclerosis? Findings
from the Rotterdam Study. Stroke 28: 2442–2447.
24. Lange LA, Carlson CS, Hindorff LA, Lange EM, Walston J, et al. (2006)
Association of polymorphisms in the CRP gene with circulating C-reactive
protein levels and cardiovascular events. JAMA 296: 2703–2711.
25. Lawlor DA, Harbord RM, Timpson NJ, Lowe GDO, Rumley A, et al. (2008)
The assocation of C-reactive protein and CRP genotype with coronary heart
disease: Findings from five studies with 4,610 cases amongst 18,637 participants.
PLoS ONE. In press.
26. Verzilli C, Shah T, Casas JP, Chapman J, Sandhu M, et al. (2008) Bayesian
meta-analysis of genetic association studies with different sets of markers.
Am J Hum Genet 82: 859–872.
27. Pai JK, Mukamal KJ, Rexrode KM, Rimm EB (2008) C-reactive protein (CRP)
gene polymorphisms, CRP levels, and risk of incident coronary heart disease in
two nested case-control studies. PLoS ONE 3: e1395.
28. CRP CHD Genetics Collaboration (2008) Collaborative pooled analysis of data
on C-reactive protein gene variants and coronary disease: judging causality by
Mendelian randomization. Eur J Epidemiol 23: 531–540.
29. Davey Smith G, Ebrahim S (2005) What can mendelian randomisation tell us
about modifiable behavioural and environmental exposures? BMJ 330:
1076–1079.
30. Zee RY, Ridker PM (2002) Polymorphism in the human C-reactive protein
(CRP) gene, plasma concentrations of CRP, and the risk of future arterial
thrombosis. Atherosclerosis 162: 217–219.
31. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, et al. (2003) Human
CRP gene polymorphism influences CRP levels: implications for the prediction
and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 23:
2063–2069.
32. Russell AI, Cunninghame Graham DS, Shepherd C, Roberton CA, Whittaker J,
et al. (2004) Polymorphism at the C-reactive protein locus influences gene
expression and predisposes to systemic lupus erythematosus. Hum Mol Genet
13: 137–147.
33. Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, et al. (2005)
Polymorphisms within the C-reactive protein (CRP) promoter region are
associated with plasma CRP levels. Am J Hum Genet 77: 64–77.
34. Kovacs A, Green F, Hansson LO, Lundman P, Samnega° rd A, et al. (2005) A
novel common single nucleotide polymorphism in the promoter region of the Creactive
protein gene associated with the plasma concentration of C-reactive
protein. Atherosclerosis 178: 193–198.
35. Szalai AJ, Alarcon GS, Calvo-Alen J, Toloza SM, McCrory MA, et al. (2005)
Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA):
Association between C-reactive protein (CRP) gene polymorphisms and vascular
events. Rheumatology (Oxford) 44: 864–868.
36. Miller DT, Zee RY, Suk Danik J, Kozlowski P, Chasman DI, et al. (2005)
Association of common CRP gene variants with CRP levels and cardiovascular
events. Ann Hum Gen 69: 623–638.
37. Suk HJ, Ridker PM, Cook NR, Zee RY (2005) Relation of polymorphism within
the C-reactive protein gene and plasma CRP levels. Atherosclerosis 178:
139–145.
38. Kathiresan S, Larson MG, Vasan RS, Guo CY, Gona P, et al. (2006)
Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms
to interindividual variability in serum C-reactive protein level.
Circulation 113: 1415–1423.
39. Staiger D, Stock JH (1997) Instrumental Variables Regression with Weak
Instruments. Econometrica: Journal of the Econometric Society 65: 557–586.
40. Cardon LR, Palmer LJ (2003) Population stratification and spurious allelic
association. Lancet 361: 598–604.
41. Knowler WC, Williams RC, Pettitt DJ, Steinberg AG (1988) Gm3;5,13,14 and
type 2 diabetes mellitus: an association in American Indians with genetic
admixture. Am J Hum Genet 43: 520–526.
42. Gelernter J, Goldman D, Risch N (1993) The A1 allele at the D2 dopamine
receptor gene and alcoholism. A reappraisal. JAMA 269: 1673–1677.
43. Szalai AJ, Wu J, Lange EM, McCrory MA, Langefeld CD (2005) Singlenucleotide
polymorphisms in the C-reactive protein (CRP) gene promoter that
affect transcription factor binding, alter transcriptional activity, and associate
with differences in baseline serum CRP level. J Mol Med 83: 440–447.
44. Timpson NJ, Davey Smith G, Ebrahim S (2006) Letter by Timpson et al
regarding article, ‘‘Contribution of clinical correlates and 13 C-reactive protein
gene polymorphisms to interindividual variability in serum C-reactive protein
level’’. Circulation 114: e256.
45. Ridker PM, Pare G, Parker A, Zee RY, Danik JS, et al. (2008) Loci related to
metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR
associate with plasma C-reactive protein: the Women’s Genome Health Study.
Am J Hum Genet 82: 1185–1192.
46. Debat V, David P (2006) Mapping phenotypes: canalization, plasticity and
developmental stability. Trends in Ecology & Evolution 16: 555–561.
47. Reilly MP, Wolfe ML, Localio AR, Rader DJ (2003) C-reactive protein and
coronary artery calcification: The Study of Inherited Risk of Coronary
Atherosclerosis (SIRCA). Arterioscler Thromb Vasc Biol 23: 1851–1856.
48. de Maat MP, Trion A (2004) C-reactive protein as a risk factor versus risk
marker. Curr Opin Lipidol 15: 651–657.
49. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, et al. (2003) Effect of
weight loss and lifestyle changes on vascular inflammatory markers in obese
women: a randomized trial. JAMA 289: 1799–1804.
50. O’Brien KD, Brehm BJ, Seeley RJ, Bean J, Wener MH, et al. (2005) Dietinduced
weight loss is associated with decreases in plasma serum amyloid a and
C-reactive protein independent of dietary macronutrient composition in obese
subjects. J Clin Endocrin Metabol 90: 2244–2249.
51. Tzoulaki I, Ja¨ rvelin MR, Hartikainen AL, Leinonen M, Pouta A, et al. (2008)
Size at birth, weight gain over the life course, and low-grade inflammation in young adulthood: northern Finland 1966 birth cohort study. Eur Heart J 29:
1049–1056.
52. Yeh ET, Willerson JT (2003) Coming of age of C-reactive protein: using
inflammation markers in cardiology. Circulation 107: 370–371.
53. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, et al.
(2006) Targeting C-reactive protein for the treatment of cardiovascular disease.
Nature 440: 1217–1221.
54. Marmot MG, Davey Smith G, Stansfeld S, Patel C, North F, et al. (1991) Health
inequalities among British civil servants: the Whitehall II study. Lancet 337:
1387–1393.
55. Rose GA, Blackburn H, Gillum RF, Prineas RJ (1982) Cardiovascular Survey
Methods. 2nd ed. Geneva: World Health Organization. 165 p.
56. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, et al.
(1994) Myocardial infarction and coronary deaths in the World Health
Organization MONICA Project. Registration procedures, event rates, and
case-fatality rates in 38 populations from 21 countries in four continents.
Circulation 90: 583–612.